Skip to main content
. 2021 Mar 19;5:PO.20.00321. doi: 10.1200/PO.20.00321

FIG 2.

FIG 2.

Molecular response and response to pembrolizumab-based therapy. (A) The association between molecular response and RECIST response at week-9 on therapy for the 17 patients with a CR or PR, 22 patients with SD, nine patients with PD, and three patients without a 9-week RECIST response assessment. (B) Association between molecular response and RECIST response at 6 months for the 33 patients achieving a DCB and 17 patients with an NDB. (C) Swimmer plots for each patient showing the duration of pembrolizumab-based therapy arranged by patients with a molecular response (blue) and without a molecular response (red). Patients treated with pembrolizumab monotherapy are denoted with a gold box to the left of the horizontal bar and those treated with pembrolizumab plus chemotherapy with a purple box. CR, complete response; DCB, durable clinical benefit; NA, RECIST not available; NDR, no durable benefit; PD, progressive disease; PR, partial response; SD, stable disease.